DK2808028T3 - Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof - Google Patents

Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof Download PDF

Info

Publication number
DK2808028T3
DK2808028T3 DK12851748.9T DK12851748T DK2808028T3 DK 2808028 T3 DK2808028 T3 DK 2808028T3 DK 12851748 T DK12851748 T DK 12851748T DK 2808028 T3 DK2808028 T3 DK 2808028T3
Authority
DK
Denmark
Prior art keywords
cd300a
mice
medical agent
antibody
activity modulator
Prior art date
Application number
DK12851748.9T
Other languages
English (en)
Inventor
Akira Shibuya
Chigusa Oda
Satoko Tahara
Tsukasa Nabekura
Gamage Udayanga Sanath Kankanam
Haruka Miki
Syuichi Iino
Original Assignee
Univ Tsukuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tsukuba filed Critical Univ Tsukuba
Application granted granted Critical
Publication of DK2808028T3 publication Critical patent/DK2808028T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK12851748.9T 2011-11-21 2012-11-07 Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof DK2808028T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011254151 2011-11-21
PCT/JP2012/078898 WO2013077186A1 (ja) 2011-11-21 2012-11-07 活性調節剤、これを含有する医薬品、ＣＤ３００ａ遺伝子欠損マウスの使用および抗ＣＤ３００ａ抗体

Publications (1)

Publication Number Publication Date
DK2808028T3 true DK2808028T3 (da) 2019-10-07

Family

ID=48469634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12851748.9T DK2808028T3 (da) 2011-11-21 2012-11-07 Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof

Country Status (6)

Country Link
US (2) US10519233B2 (da)
EP (1) EP2808028B1 (da)
JP (1) JP6124261B2 (da)
DK (1) DK2808028T3 (da)
ES (1) ES2748022T3 (da)
WO (1) WO2013077186A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519233B2 (en) 2011-11-21 2019-12-31 University Of Tsukuba Activity modulator, medicinal agent comprising same, use of CD300A gene-deficient mouse, and anti-CD300A antibody
US9850309B2 (en) * 2012-11-07 2017-12-26 University Of Tsukuba Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
DE102014202609B4 (de) 2014-02-13 2020-06-04 tooz technologies GmbH Aminkatalysierte Thiolhärtung von Epoxidharzen
WO2017135277A1 (ja) * 2016-02-03 2017-08-10 国立感染症研究所長が代表する日本国 ノロウイルスが増殖可能な遺伝子組換え培養細胞、及び、その用途
US20210188973A1 (en) 2017-11-30 2021-06-24 University Of Tsukuba Activity Modulator
AU2022316209A1 (en) 2021-07-20 2024-02-22 Regeneron Pharmaceuticals, Inc. Butyrophilin-like 2 agents for treating inflammatory disorders
CN116139275B (zh) * 2021-11-19 2026-02-17 复旦大学 Cd300ld抑制剂在制备预防、诊断或治疗肿瘤产品中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007201753B2 (en) 1998-07-22 2008-11-27 Osprey Pharmaceuticals Usa, Inc. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
EP1559786A4 (en) 2002-10-30 2006-01-11 Chugai Pharmaceutical Co Ltd MEMBRANE PROTEINS FROM MAST CELLS
JP2004173531A (ja) 2002-11-25 2004-06-24 Inst Of Physical & Chemical Res 免疫受容体タンパク質
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
KR100635540B1 (ko) 2004-10-12 2006-10-18 경북대학교 산학협력단 신규한 염증성 질환의 예방 또는 치료용 약학적 조성물
AU2006243905B2 (en) * 2005-05-13 2011-09-01 The Feinstein Institute For Medical Research Milk fat globule epidermal growth factor-factor VIII and sepsis
WO2007101254A2 (en) 2006-02-28 2007-09-07 Telos Pharmaceuticals Llc Compositions and methods for the treatment of immune system disorders
JP2007297379A (ja) 2006-04-06 2007-11-15 Ajinomoto Co Inc 樹状細胞の機能賦活化剤
WO2008064031A2 (en) 2006-11-13 2008-05-29 Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
JP2010519206A (ja) * 2007-02-16 2010-06-03 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連使用のための置換縮合環化合物
JP2011516609A (ja) 2008-04-14 2011-05-26 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ抗炎症活性及びその使用
KR101291764B1 (ko) 2011-03-04 2013-08-01 경북대학교 산학협력단 ＣＤ３００ａ 합성 펩타이드 및 이를 함유하는 면역 반응 조절용 조성물
US10519233B2 (en) 2011-11-21 2019-12-31 University Of Tsukuba Activity modulator, medicinal agent comprising same, use of CD300A gene-deficient mouse, and anti-CD300A antibody

Also Published As

Publication number Publication date
JP6124261B2 (ja) 2017-05-10
EP2808028A4 (en) 2016-04-13
JPWO2013077186A1 (ja) 2015-04-27
WO2013077186A1 (ja) 2013-05-30
US10519233B2 (en) 2019-12-31
US20200040077A1 (en) 2020-02-06
ES2748022T3 (es) 2020-03-12
EP2808028B1 (en) 2019-09-04
US20150047059A1 (en) 2015-02-12
EP2808028A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
IL288070B (en) Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
IL287381A (en) Pharmaceutical preparations of human rpe cells and uses thereof
IL280819A (en) Adeno-associated virus virions with variant capsid and methods of use thereof
FI20100196A0 (fi) Matalanikkelinen austeniittinen ruostumaton teräs ja teräksen käyttö
PL2552959T3 (pl) Przeciwciała przeciwko MUC16 i metody stosowania
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
EP2791159A4 (en) MODIFIED NUCLEIC ACIDS AND ACUTE TREATMENT USES THEREOF
EP2788376A4 (en) NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
DK3275539T3 (da) Hydrogenbehandlingskatalysatorer og fremstilling deraf
EP2621439A4 (en) Disuposable Diaper
HUE055505T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HRP20181351T1 (hr) Ciljani terapeutski fuzijski proteini lizosomalnog enzima i njihova uporaba
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
DK2808028T3 (da) Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof
PL2771037T3 (pl) Środki terapeutyczne i ich zastosowania
DK3434775T3 (da) Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf
EP2678017A4 (en) ASYMMETRIC UREA AND MEDICAL USES THEREOF
EP2774535A4 (en) ELECTROCARDIOGRAPH AND BIOELECTRODE PAD
HRP20181599T1 (hr) Proizvodnja i upotreba bakterijskog histamina
BR112014006291A2 (pt) composição e utilização da composição
DK2593060T3 (da) Engangsble
EP2682145A4 (en) SYRINGE AND SYRINGE ASSEMBLY
DK2844233T3 (da) Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
IL225389A0 (en) Antibody compositions and methods of use